Real-world drug usage survival of spironolactone versus oral antibiotics for the management of female patients with acne - 24/07/19
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: Supported in part through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS 1P30AR069589-01). Dr Barbieri is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number T32-AR-007465 and receives partial salary support through a Pfizer Fellowship in Dermatology Patient-Oriented Research grant to the Trustees of the University of Pennsylvania. |
|
Conflicts of interest: None disclosed. |
|
Disclaimer: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?